id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9325 R32513 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Cardiac septal | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.89 [0.65;5.50] C excluded (control group) |
6/333 8/833 | 14 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9326 R32520 |
Veiby (Valproate) (Controls unexposed, disease free) (Mixed indications), 2014 | Cardiac septal | throughout pregnancy | population based cohort retrospective | unexposed, disease free | Adjustment: Yes | 2.69 [1.20;6.03] | 6/333 5,400/771,412 | 5,406 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9309 R32427 |
Källén (Valproate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Septum defect | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.91 [0.94;3.90] C excluded (control group) |
17/697 14/1,084 | 31 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9310 R32435 |
Källén (Valproate) (Controls unexposed, NOS) (Indications NOS), 2013 | Septum defect | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 2.66 [1.55;4.27] | 17/697 11,155/1,575,847 | 11,172 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 2.67 [1.74;4.10] | 16,578 | 1,030 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, disease free) (Mixed indications; 2: Valproate) (Controls unexposed, NOS) (Indications NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9309, 9325